Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ADG206 |
Synonyms | |
Therapy Description |
ADG206 is an agonistic antibody that targets TNFRSF9 (CD137), potentially leading to increased costimulatory signaling, increased T-cell response, and antitumor activity (Cancer Res (2022) 82 (12_Supplement): 2868). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADG206 | ADG-206|ADG 206 | TNFRSF9 Antibody 30 | ADG206 is an agonistic antibody that targets TNFRSF9 (CD137), potentially leading to increased costimulatory signaling, increased T-cell response, and antitumor activity (Cancer Res (2022) 82 (12_Supplement): 2868). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05614258 | Phase I | ADG206 | Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors | Recruiting | AUS | 0 |